Osteomyelitis : Comparison Dalbavancin in the treatment of acute

A Phase 2, Multicenter, Open-label, Randomized, Comparator-controlled Trial of the Safety and Efficacy of Dalbavancin versus Active Comparator in Adult Patients with Osteomyelitis Known or Suspected to be Due to Gram-positive Organisms PROTOCOL: 3026-201-008

November 22, 2017

  • Clinical Trial Information

    Trial Contact: Willett, Paula

    Trial Phone: 321.841.9623

  • IRB No: 17.038.04

    Principal Investigator: Mary Catherine Bowman, MD

    Sub Investigators: Giordano, Philip MD; Weber, Kurt MD

    Phase: Drug: Phase II

    Age Group: Adult

    Secondary Protocol No: PROTOCOL: 3026-201-008

    Treatment: Medication

    Applicable Disease Sites: Osteomyelitis

    Therapies Involved: Dalbavancin

    ClinicalTrials.gov ID: NCT03091439

  • Objective

    Compare the safety and efficacy of Dalbavancin in comparison to standard of care therapy in the treatment of acute osteomyelitis

  • Key Eligibility

    > 18yrs of age
    Acute Osteomelitis